Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma
Background To evaluate the efficacy and safety of chemo-immunotherapy combined with residual lesions irradiation of advanced stage esophageal squamous cell carcinoma.Methods Treatment-naïve patients with radiologically and histologically confirmed advanced or metastatic squamous-cell esophageal carc...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20565623.2025.2527497 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849431058043371520 |
|---|---|
| author | Xiang Han Zhongfa Zhang Ling Zhang Yunhong You Xiajuan Xu Yuchao Niu Zhimei Zhao Xiuhui Guo Youxin Ji Qiuyu Hou Keke Nie |
| author_facet | Xiang Han Zhongfa Zhang Ling Zhang Yunhong You Xiajuan Xu Yuchao Niu Zhimei Zhao Xiuhui Guo Youxin Ji Qiuyu Hou Keke Nie |
| author_sort | Xiang Han |
| collection | DOAJ |
| description | Background To evaluate the efficacy and safety of chemo-immunotherapy combined with residual lesions irradiation of advanced stage esophageal squamous cell carcinoma.Methods Treatment-naïve patients with radiologically and histologically confirmed advanced or metastatic squamous-cell esophageal carcinoma were enrolled. Participants received four cycles of the TP regimen combined with the PD-1 inhibitor sintilimab. Patients who completed four cycles of chemo-immunotherapy with stable disease (SD) or partial response (PR) subsequently received 50 Gy of radiation in 25 fractions for residual tumors. Maintenance sintilimab therapy was administered every 21 days for up to 31 cycles or until disease progression or intolerable toxicity occurred.Results A total of 39 patients were enrolled in this study, of whom 30 were evaluable for efficacy and toxicity. The complete response (CR) rate was 6.7% (2/30), the partial response (PR) rate was 53.3% (16/30). The median depth of response (DpR) was 34.5% for chemo-immunotherapy and increased to 64.0% after radiotherapy. The progression-free survival (PFS) was 16.4 months, while overall survival (OS) has not yet been reached.Conclusions Chemo-immunotherapy followed by radiotherapy for residual tumors and maintenance sintilimab, demonstrated high response rates, prolonged PFS, and tolerable toxicity as a first-line treatment for patients with advanced or metastatic esophageal squamous-cell carcinoma. |
| format | Article |
| id | doaj-art-b6135cfd2c58487e89a0e92ee8422312 |
| institution | Kabale University |
| issn | 2056-5623 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-b6135cfd2c58487e89a0e92ee84223122025-08-20T03:27:44ZengTaylor & Francis GroupFuture Science OA2056-56232025-12-0111110.1080/20565623.2025.2527497Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinomaXiang Han0Zhongfa Zhang1Ling Zhang2Yunhong You3Xiajuan Xu4Yuchao Niu5Zhimei Zhao6Xiuhui Guo7Youxin Ji8Qiuyu Hou9Keke Nie10Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaDepartment of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaDepartment of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaDepartment of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaDepartment of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaDepartment of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaDepartment of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaDepartment of Oncology, Pingdu People’s Hospital, Qingdao, ChinaDepartment of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaDepartment of Thoracic Surgery, Qingdao the 8th People’s Hospital, Qingdao, ChinaDepartment of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, ChinaBackground To evaluate the efficacy and safety of chemo-immunotherapy combined with residual lesions irradiation of advanced stage esophageal squamous cell carcinoma.Methods Treatment-naïve patients with radiologically and histologically confirmed advanced or metastatic squamous-cell esophageal carcinoma were enrolled. Participants received four cycles of the TP regimen combined with the PD-1 inhibitor sintilimab. Patients who completed four cycles of chemo-immunotherapy with stable disease (SD) or partial response (PR) subsequently received 50 Gy of radiation in 25 fractions for residual tumors. Maintenance sintilimab therapy was administered every 21 days for up to 31 cycles or until disease progression or intolerable toxicity occurred.Results A total of 39 patients were enrolled in this study, of whom 30 were evaluable for efficacy and toxicity. The complete response (CR) rate was 6.7% (2/30), the partial response (PR) rate was 53.3% (16/30). The median depth of response (DpR) was 34.5% for chemo-immunotherapy and increased to 64.0% after radiotherapy. The progression-free survival (PFS) was 16.4 months, while overall survival (OS) has not yet been reached.Conclusions Chemo-immunotherapy followed by radiotherapy for residual tumors and maintenance sintilimab, demonstrated high response rates, prolonged PFS, and tolerable toxicity as a first-line treatment for patients with advanced or metastatic esophageal squamous-cell carcinoma.https://www.tandfonline.com/doi/10.1080/20565623.2025.2527497Esophageal squamous-cell carcinomachemotherapyimmunotherapyresidual tumorirradiation |
| spellingShingle | Xiang Han Zhongfa Zhang Ling Zhang Yunhong You Xiajuan Xu Yuchao Niu Zhimei Zhao Xiuhui Guo Youxin Ji Qiuyu Hou Keke Nie Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma Future Science OA Esophageal squamous-cell carcinoma chemotherapy immunotherapy residual tumor irradiation |
| title | Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma |
| title_full | Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma |
| title_fullStr | Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma |
| title_full_unstemmed | Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma |
| title_short | Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma |
| title_sort | chemo immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma |
| topic | Esophageal squamous-cell carcinoma chemotherapy immunotherapy residual tumor irradiation |
| url | https://www.tandfonline.com/doi/10.1080/20565623.2025.2527497 |
| work_keys_str_mv | AT xianghan chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma AT zhongfazhang chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma AT lingzhang chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma AT yunhongyou chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma AT xiajuanxu chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma AT yuchaoniu chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma AT zhimeizhao chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma AT xiuhuiguo chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma AT youxinji chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma AT qiuyuhou chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma AT kekenie chemoimmunotherapysequentialwithradiotherapyinadvancedormetastaticesophagealsquamouscellcarcinoma |